DPP-4

Cat. No.

A43560

CAS No.

855790-98-6

SGP8

SGP8 (IAVPGEVA) is a DPP4 inhibitor that demonstrates significant modulation of lipid metabolism, inflammation, and fibrosis. By inhibiting DPP4 activity, SGP8 affects the JNK-c-Jun signaling pathway and shows potential therapeutic applications in the treatment of non-alcoholic steatohepatitis (NASH). This octapeptide, derived from the hydrolysis of soybean 11S globulin, serves as a valuable tool for research in metabolic disorders and related inflammatory conditions.

Cat. No.

A43563

CAS No.

3035300-36-5

DPP-4-IN-15

DPP-4-IN-15 is a non-competitive inhibitor of dipeptidyl peptidase-4 (DPP-4), exhibiting an IC50 value of 8.24 μM. This compound effectively modulates the activity of DPP-4, an enzyme involved in glucose metabolism and insulin regulation. DPP-4-IN-15 is primarily utilized in diabetes research, providing insights into the potential therapeutic effects of DPP-4 inhibition on glycemic control and related metabolic disorders.

Cat. No.

A43566

CAS No.

160219-74-9

Fluostatin A

Fluostatin A is a potent inhibitor of dipeptidyl peptidase III (DPP-III), demonstrating an IC50 value of 0.44 μg/mL with the substrate arginyl-arginine-2-naphthalene formamide. By modulating DPP-III activity, Fluostatin A plays a significant role in studies related to peptide metabolism and signaling pathways. This compound is suitable for research applications in diabetes, cardiovascular disease, and other metabolic disorders targeting DPP-III enzymatic regulation.

Cat. No.

A43567

CAS No.

1163719-08-1

AMG-222 tosylate

AMG-222 tosylate is a potent DPP-IV inhibitor, primarily employed in the investigation of type II diabetes. By modulating the activity of the DPP-IV enzyme, AMG-222 tosylate facilitates enhanced insulin secretion and improved glycemic control. This compound is valuable for research aimed at understanding the mechanisms of glucose homeostasis and developing therapeutic approaches for managing diabetes.

Cat. No.

A43568

CAS No.

158906-40-2

Fluostatin B

Fluostatin B is a dipeptidyl peptidase 3 (DPP-3) inhibitor with an IC50 value of 24 µg/mL. As a natural product derived from Streptomyces, this compound exhibits potential biological activity in modulating peptide metabolism. Fluostatin B is relevant for research applications focused on understanding DPP-3's role in various physiological processes and exploring its implications in disease states such as diabetes and cancer.

Cat. No.

A43570

CAS No.

103192-50-3

H-Gly-Pro-Hyp-OH acetate

H-Gly-Pro-Hyp-OH acetate functions as a dipeptidyl peptidase 4 (DPP-4) inhibitor, exhibiting an IC50 value of 2.51 mM. This compound has shown promise in the investigation of diabetes-related pathways and therapeutic strategies. Its ability to modulate DPP-4 activity makes it a valuable reagent for research in metabolic disorders and glucose homeostasis.

Cat. No.

A43574

CAS No.

91533-02-7

HTS13517

HTS13517 is a selective inhibitor of Dipeptidyl Peptidase IV (DPP4), exhibiting an IC50 value of 10.73 μM. This compound is relevant for studies investigating the modulation of glucose metabolism and the regulation of incretin hormones. Its applications include diabetes research and the exploration of therapeutic strategies targeting metabolic disorders.

Cat. No.

A43575

CAS No.

1601479-87-1

Garvagliptin

Synonyms: ZYDPLA1

Garvagliptin is a selective and orally active dipeptidyl peptidase-4 (DPP4) inhibitor, achieving an IC50 of 2.99 nM against human recombinant DPP IV. Its primary mechanism facilitates the enhancement of incretin levels, thereby exhibiting antihyperglycemic effects. Garvagliptin is widely utilized in diabetes research to explore its potential in glycemic control and metabolic regulation.

Cat. No.

A51419

CAS No.

200203-20-9

HIV-1 tat Protein (1-9)

HIV-1 tat Protein (1-9) targets Dipeptidyl Peptidase IV (DP IV) and functions as an inhibitor of this enzyme. This peptide has been implicated in the immunosuppression of non-HIV-1-infected T cells, making it relevant for studies related to acquired immune deficiency syndrome (AIDS). Researchers can synthesize HIV-1 tat Protein (1-9) using the Fmoc (N-(9-fluorenyl)methoxycarbonyl) technique with peptide synthesizer 431A. It serves as a valuable reagent for investigating the mechanisms of HIV-1 pathogenesis and potential therapeutic strategies.